Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 32, Number 9—September 2026
Research
Posttuberculosis Consequences on Tuberculosis Prevention Effectiveness and Cost-effectiveness among New Immigrants, Canada
Aotikuer Ainiwaer, Aashna Uppal, Kevin Schwartzman, Kamila Romanowski, Sarah K. Brode, James C. Johnston, and Jonathon R. Campbell
Table 3
Effects of post-tuberculosis consequences on incremental outcomes between intervention and status quo*
| Incremental outcomes between status quo and intervention | Acute TB consequences only, referent | Post-TB elevated risk for death | Post-TB persistent disease |
Post-TB healthcare costs | All post-TB consequences |
|---|---|---|---|---|---|
| Absolute incremental cost, | 19.4 million (4.1–38.0 million) | 19.4 million (4.1–38.0 million) | 19.4 million (4.1–38.0 million) | 18.7 million (3.3–37.3 million) | 18.7 million (3.3–37.3 million) |
| Relative incremental cost compared with no post-TB consequences |
1.0 |
1.0 |
1.0 |
0.96 (0.87–0.99) |
0.96 (0.87–0.99) |
| Absolute incremental QALY | 82 (28–124) | 138 (76–198) | 131 (65–200) | 82 (28–124) | 186 (109–267) |
| Relative incremental QALY ratio compared with no post-TB consequences |
1.0 |
1.7 (1.3–3.0) |
1.7 (1.2–2.7) |
1.0 |
2.4 (1.6–4.4) |
| Absolute incremental TB-related deaths | −12 (−15 to −7) | −25 (−33 to −18) | −12 (−15 to −7) | −12 (−15 to −7) | −25 (−33 to −18) |
| Relative incremental TB deaths ratio compared with no post-TB consequences |
1.0 |
2.2 (1.6–3.0) |
1.0 |
1.0 |
2.2 (1.6–3.0) |
| ICER | $235,088 | $140,146 | $147,595 | $227,340 | $100,742 |
| <$50,000, % | 3 | 5 | 5 | 3 | 11 |
| $50,000–<$100,000, % | 8 | 27 | 25 | 9 | 53 |
| $100,000–<$150,000, % | 21 | 59 | 54 | 24 | 81 |
*Incremental outcomes refer to the difference between intervention and status quo per 400,000 persons. Values are (95% uncertainty range). ICER, incremental cost-effectiveness ratios; QALY, quality adjusted life year; TB, tuberculosis.
Page created: July 30, 2026
Page updated: August 17, 2026
Page reviewed: August 17, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.